Physician profile
Betsy Benjamin
NPI 1750957809
$531.05
in general payments reported to CMS, 2019-2025
11 companies · $37.47 in 2025
The $37.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.23 · 2022: $148 · 2023: $211 · 2024: $114 · 2025: $37.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $122.09 | 2023 | Otezla |
| Genzyme Corporation | $97.68 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $92.80 | 2022 | |
| Novo Nordisk INC | $54.77 | 2023-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.88 | 2023 | Ninlaro |
| Daxor Corporation | $22.26 | 2023 | Bva-100 |
| Alexion Pharmaceuticals, INC. | $20.31 | 2023 | Strensiq |
| Vapotherm INC | $20.23 | 2021 | |
| Glaxosmithkline, LLC. | $17.86 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.